Jeffrey Lieberman, M.D. - Publications

Affiliations: 
Psychiatry Columbia University, New York, NY 

349 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, Bryois J, Chen CY, Dennison CA, Hall LS, Lam M, Watanabe K, Frei O, Ge T, Harwood JC, ... ... Lieberman J, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. PMID 35396580 DOI: 10.1038/s41586-022-04434-5  0.313
2022 Stone WS, Phillips MR, Yang LH, Kegeles LS, Susser ES, Lieberman JA. Neurodegenerative model of schizophrenia: Growing evidence to support a revisit. Schizophrenia Research. 243: 154-162. PMID 35344853 DOI: 10.1016/j.schres.2022.03.004  0.356
2021 Zoghbi AW, Dhindsa RS, Goldberg TE, Mehralizade A, Motelow JE, Wang X, Alkelai A, Harms MB, Lieberman JA, Markx S, Goldstein DB. High-impact rare genetic variants in severe schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34903660 DOI: 10.1073/pnas.2112560118  0.373
2021 Paul SM, Breier A, Lieberman JA, Brannan SK, Sawchak S, Miller AC. Clinical Trial of New Drug for Schizophrenia. Reply. The New England Journal of Medicine. 384: e105. PMID 34161716 DOI: 10.1056/NEJMc2104965#sa2  0.317
2020 Stone WS, Cai B, Liu X, Grivel MM, Yu G, Xu Y, Ouyang X, Chen H, Deng F, Xue F, Li H, Lieberman JA, Keshavan MS, Susser ES, Yang LH, et al. Association Between the Duration of Untreated Psychosis and Selective Cognitive Performance in Community-Dwelling Individuals With Chronic Untreated Schizophrenia in Rural China. Jama Psychiatry. PMID 32639517 DOI: 10.1001/Jamapsychiatry.2020.1619  0.343
2020 Maes MS, Lu JY, Tiwari AK, Freeman N, de Luca V, Müller DJ, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL, Zai CC. Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia. Drug Development Research. PMID 32394511 DOI: 10.1002/Ddr.21681  0.357
2020 Kantrowitz JT, Javitt DC, Freedman R, Sehatpour P, Kegeles LS, Carlson M, Sobeih T, Wall MM, Choo TH, Vail B, Grinband J, Lieberman JA. Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 32015461 DOI: 10.1038/S41386-020-0628-9  0.336
2020 Clelland CL, Kantrowitz JT, Choo T, Clelland JD, Lieberman JA. Adjunctive sapropterin dihydrochloride treatment in schizophrenia: A positive proof-of-concept, rater-blind, randomized, multivitamin-controlled study. Schizophrenia Research. PMID 31973997 DOI: 10.1016/J.Schres.2019.12.039  0.364
2020 Correll CU, Davis RE, Weingart M, Saillard J, O'Gorman C, Kane JM, Lieberman JA, Tamminga CA, Mates S, Vanover KE. Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial. Jama Psychiatry. PMID 31913424 DOI: 10.1001/Jamapsychiatry.2019.4379  0.389
2020 Yoshida K, Maciukiewicz M, Marshe V, Tiwari A, Brandl E, Lieberman J, Meltzer H, Kennedy J, Mueller D. M172. POLYGENIC RISK SCORES ANALYSES IN ANTIPSYCHOTIC-INDUCED WEIGHT GAIN Schizophrenia Bulletin. 46: S202-S202. DOI: 10.1093/Schbul/Sbaa030.484  0.332
2019 Lieberman JA, Small SA, Girgis RR. Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality. The American Journal of Psychiatry. 176: 794-810. PMID 31569988 DOI: 10.1176/Appi.Ajp.2019.19080865  0.359
2019 Lawrence RE, Appelbaum PS, Lieberman JA. Are Placebo-Controlled, Relapse Prevention Trials in Schizophrenia Research Still Necessary or Ethical? Jama Psychiatry. PMID 30969331 DOI: 10.1001/jamapsychiatry.2019.0275  0.321
2019 Fleming LM, Javitt DC, Carter CS, Kantrowitz JT, Girgis RR, Kegeles LS, Ragland JD, Maddock RJ, Lesh TA, Tanase C, Robinson J, Potter WZ, Carlson M, Wall MM, Choo TH, ... Lieberman J, et al. A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms. Neuroimage. Clinical. 22: 101739. PMID 30852397 DOI: 10.1016/J.Nicl.2019.101739  0.48
2019 Abi-Dargham A, Van Snellenberg J, Girgis R, Slifstein M, Javitch J, Lieberman J. 118. The Challenges of Testing D1 Agonists in Schizophrenia Biological Psychiatry. 85: S49. DOI: 10.1016/J.Biopsych.2019.03.132  0.436
2019 Lieberman J, Goff D, Marder S, Lahti A, Javitt D, Kantrowitz J, Girgis R, Grinband J, Kegeles L, Wall M, Chou T. 117. Biomarker Assessment of Dose Dependent Target Engagement of mGluR-2,3 Partial Agonist for Schizophrenia Treatment Biological Psychiatry. 85: S49. DOI: 10.1016/J.Biopsych.2019.03.131  0.432
2018 Lu JY, Tiwari AK, Zai GC, Rastogi A, Shaikh SA, Mueller DJ, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Wong AHC, Kennedy JL, Zai CC. Association study of Disrupted-In-Schizophrenia-1 Gene variants and Tardive Dyskinesia. Neuroscience Letters. PMID 30118782 DOI: 10.1016/J.Neulet.2018.08.007  0.321
2018 Girgis RR, Zoghbi AW, Javitt DC, Lieberman JA. The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review. Journal of Psychiatric Research. PMID 30055853 DOI: 10.1016/J.Jpsychires.2018.07.006  0.358
2018 Lieberman JA. Disease modifying effects of antipsychotic drugs in schizophrenia: a clinical and neurobiological perspective. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 17: 163-165. PMID 29856557 DOI: 10.1002/Wps.20543  0.355
2018 Lieberman JA, Girgis RR, Brucato G, Moore H, Provenzano F, Kegeles L, Javitt D, Kantrowitz J, Wall MM, Corcoran CM, Schobel SA, Small SA. Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention. Molecular Psychiatry. PMID 29311665 DOI: 10.1038/Mp.2017.249  0.361
2018 Maciukiewicz M, Tiwari A, Goncalves V, Zai C, Brandl E, Freeman N, Lieberman J, Meltzer H, Laughlin C, Nurmi E, Kennedy J, Mueller D. F1. GENOME-WIDE ASSOCIATION STUDIES SUGGESTED ASSOCIATION BETWEEN DGKB AND ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN EUROPEANS AND AFRICAN AMERICANS Schizophrenia Bulletin. 44: S218-S218. DOI: 10.1093/Schbul/Sby017.532  0.378
2017 Zoghbi AW, Lieberman JA. Alive but not well: the limited validity but continued utility of the concept of schizophrenia. Psychological Medicine. 1-2. PMID 29072155 DOI: 10.1017/S0033291717001969  0.4
2017 Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia - a short version for primary care. International Journal of Psychiatry in Clinical Practice. 1-9. PMID 28498090 DOI: 10.1080/13651501.2017.1291839  0.45
2017 Goff DC, Falkai P, Fleischhacker WW, Girgis RR, Kahn RM, Uchida H, Zhao J, Lieberman JA. The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia. The American Journal of Psychiatry. appiajp201716091016. PMID 28472900 DOI: 10.1176/Appi.Ajp.2017.16091016  0.33
2017 Stroup TS, Lieberman JA. Raising the standard of care for schizophrenia is an achievable goal. The Australian and New Zealand Journal of Psychiatry. 4867417700277. PMID 28374601 DOI: 10.1177/0004867417700277  0.321
2017 Chen C, Tiwari A, Zai C, Tylor D, Potkin S, Meltzer H, Lieberman J, Mueller D, Kennedy J. SU3. Preliminary Study for Association of Genome-Wide Significant Glutamate Receptor Schizophrenia Risk Variants With Clozapine Response Schizophrenia Bulletin. 43: S161-S162. DOI: 10.1093/Schbul/Sbx024.002  0.409
2017 Kennedy JL, Huang E, Tiwari AK, Zai C, Gonçalves V, Potkin S, Lieberman J, Meltzer H. Preliminary Model For The Genetic Prediction Of Clozapine Response European Neuropsychopharmacology. 27: S456. DOI: 10.1016/J.Euroneuro.2016.09.526  0.337
2016 Van Snellenberg JX, Girgis RR, Horga G, van de Giessen E, Slifstein M, Ojeil N, Weinstein JJ, Moore H, Lieberman JA, Shohamy D, Smith EE, Abi-Dargham A. Mechanisms of Working Memory Impairment in Schizophrenia. Biological Psychiatry. PMID 27056754 DOI: 10.1016/J.Biopsych.2016.02.017  0.345
2016 Taylor DL, Tiwari AK, Lieberman JA, Potkin SG, Meltzer HY, Knight J, Remington G, Müller DJ, Kennedy JL. Genetic association analysis of N-methyl-d-aspartate receptor subunit gene GRIN2B and clinical response to clozapine. Human Psychopharmacology. PMID 26876050 DOI: 10.1002/Hup.2519  0.333
2016 Huang E, Maciukiewicz M, Zai CC, Tiwari AK, Li J, Potkin SG, Lieberman JA, Meltzer HY, Müller DJ, Kennedy JL. Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response. Pharmacogenomics. 17: 103-9. PMID 26666695 DOI: 10.2217/Pgs.15.155  0.307
2015 Lieberman JA, Davis RE, Correll CU, Goff DC, Kane JM, Tamminga CA, Mates S, Vanover KE. ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. Biological Psychiatry. PMID 26444072 DOI: 10.1016/J.Biopsych.2015.08.026  0.349
2015 Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 16: 142-70. PMID 25822804 DOI: 10.3109/15622975.2015.1009163  0.443
2015 Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, Lieberman JA, et al. A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophrenia Research. 164: 136-42. PMID 25728831 DOI: 10.1016/J.Schres.2015.01.041  0.322
2015 Pouget JG, Gonçalves VF, Nurmi EL, P Laughlin C, Mallya KS, McCracken JT, Aman MG, McDougle CJ, Scahill L, Misener VL, Tiwari AK, Zai CC, Brandl EJ, Felsky D, Leung AQ, Lieberman JA, et al. Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. Pharmacogenomics. 16: 5-22. PMID 25560467 DOI: 10.2217/Pgs.14.158  0.395
2015 Dixon L, Lieberman J. Early psychosis intervention services: a work in progress. Schizophrenia Bulletin. 41: 23-4. PMID 25332408 DOI: 10.1093/Schbul/Sbu143  0.343
2015 Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Fleischhacker W, Lieberman J. P.3.d.057 Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a double-blind, placebo-controlled trial European Neuropsychopharmacology. 25: S512-S513. DOI: 10.1016/S0924-977X(15)30705-7  0.304
2014 Siever LJ, Rosell D, McClure M, Strike K, Barch DM, Harvey P, Girgis R, Lieberman J, Giakoumaki S, Bitsios P, Roussos P, Haroutunian V. THE D1 RECEPTOR AND COGNITION AND TRIAL OF A NOVEL D1 AGONIST IN THE SCHIZOPHRENIA SPECTRUM Schizophrenia Research. 153: S5-S6. DOI: 10.1016/S0920-9964(14)70017-9  0.378
2013 Lieberman JA, Dixon LB, Goldman HH. Early detection and intervention in schizophrenia: a new therapeutic model. Jama. 310: 689-90. PMID 23989167 DOI: 10.1001/Jama.2013.8804  0.302
2013 Chan LF, Zai C, Monda M, Potkin S, Kennedy JL, Remington G, Lieberman J, Meltzer HY, De Luca V. Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment? Pharmacogenomics. 14: 1273-81. PMID 23930674 DOI: 10.2217/Pgs.13.127  0.32
2013 Jarskog LF, Hamer RM, Catellier DJ, Stewart DD, Lavange L, Ray N, Golden LH, Lieberman JA, Stroup TS. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. The American Journal of Psychiatry. 170: 1032-40. PMID 23846733 DOI: 10.1176/Appi.Ajp.2013.12010127  0.317
2013 Lett TA, Chakravarty MM, Chakavarty MM, Felsky D, Brandl EJ, Tiwari AK, Gonçalves VF, Rajji TK, Daskalakis ZJ, Meltzer HY, Lieberman JA, Lerch JP, Mulsant BH, Kennedy JL, Voineskos AN. The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia. Molecular Psychiatry. 18: 443-50. PMID 23459466 DOI: 10.1038/Mp.2013.17  0.331
2013 Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, Barch DM, Buchanan RW, Csernansky JG, Goff DC, Harms MP, Javitt DC, Keefe RS, McEvoy JP, McMahon RP, ... Lieberman JA, et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 1245-52. PMID 23325325 DOI: 10.1038/Npp.2013.23  0.343
2013 Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, Duan N, Hosford DA. A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 968-75. PMID 23303043 DOI: 10.1038/Npp.2012.259  0.313
2013 Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 14: 2-44. PMID 23216388 DOI: 10.3109/15622975.2012.739708  0.451
2013 McClure RK, Styner M, Maltbie E, Lieberman JA, Gouttard S, Gerig G, Shi X, Zhu H. Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type. Psychiatry Research. 211: 1-10. PMID 23142194 DOI: 10.1016/J.Pscychresns.2012.07.001  0.34
2013 Huey ED, Nagy PL, Rodriguez-Murillo L, Manoochehri M, Goldman J, Lieberman J, Karayiorgou M, Mayeux R. C9ORF72 repeat expansions not detected in a group of patients with schizophrenia. Neurobiology of Aging. 34: 1309.e9-10. PMID 23036583 DOI: 10.1016/J.Neurobiolaging.2012.08.011  0.47
2013 Nowrouzi B, Souza RP, Zai C, Shinkai T, Monda M, Lieberman J, Volvaka J, Meltzer HY, Kennedy JL, De Luca V. Finite mixture regression model analysis on antipsychotics induced weight gain: investigation of the role of the serotonergic genes. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 224-8. PMID 22840963 DOI: 10.1016/J.Euroneuro.2012.05.008  0.315
2013 Lieberman J. Early Detection of Schizophrenia: The Time Is Now Psychiatric News. 48: 1-1. DOI: 10.1176/APPI.PN.2013.8B27  0.352
2013 Lieberman J, Pikalov A, Hsu J, Cucchiaro J, Werner P, Grossman F, Loebel A. P.3.d.051 Lurasidone in the treatment of early-stage schizophrenia: a post-hoc analysis of three pooled acute treatment studies European Neuropsychopharmacology. 23. DOI: 10.1016/S0924-977X(13)70774-0  0.413
2013 Lieberman J, Pikalov A, Hsu J, Cucchiaro J, Werner P, Grossman F, Loebel A. 1051 – Lurasidone in the treatment of early-stage schizophrenia: a post-hoc analysis of three pooled acute treatment studies European Psychiatry. 28: 1. DOI: 10.1016/S0924-9338(13)76171-6  0.372
2012 Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 13: 318-78. PMID 22834451 DOI: 10.3109/15622975.2012.696143  0.463
2012 Frazier JA, Giuliano AJ, Johnson JL, Yakutis L, Youngstrom EA, Breiger D, Sikich L, Findling RL, McClellan J, Hamer RM, Vitiello B, Lieberman JA, Hooper SR. Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. Journal of the American Academy of Child and Adolescent Psychiatry. 51: 496-505. PMID 22525956 DOI: 10.1016/J.Jaac.2012.02.001  0.35
2012 Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophrenia Research. 136: 25-31. PMID 22169248 DOI: 10.1016/J.Schres.2011.11.001  0.44
2012 Olfson M, Gerhard T, Huang C, Lieberman JA, Bobo WV, Crystal S. Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia. Schizophrenia Bulletin. 38: 845-53. PMID 21307041 DOI: 10.1093/Schbul/Sbq172  0.315
2012 Rosenheck R, Swartz M, McEvoy J, Stroup TS, Davis S, Keefe RS, Hsiao J, Lieberman J. Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. Expert Review of Pharmacoeconomics & Outcomes Research. 7: 103-11. PMID 20528436 DOI: 10.1586/14737167.7.2.103  0.415
2012 Lieberman JA. Treatment of Schizophrenia: Current Capability, Future Promise Psychiatric News. 47: 28-28. DOI: 10.1176/pn.47.3.psychnews_47_3_28-a  0.369
2011 Tiwari HK, Patki A, Lieberman J, Stroup TS, Allison DB, Leibel RL, Chung WK. Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study). Frontiers in Genetics. 2: 56. PMID 22039372 DOI: 10.3389/Fgene.2011.00056  0.344
2011 Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer MA, Welnberger DR, Karayiorgou M, Guidotti A, Gingrich J, Akbarian S, Buchanan RW, Lieberman JA, Conn PJ, Haggarty SJ, et al. Advancing drug discovery for schizophrenia. Annals of the New York Academy of Sciences. 1236: 30-43. PMID 22032400 DOI: 10.1111/J.1749-6632.2011.06216.X  0.364
2011 Shi X, Ibrahim JG, Lieberman J, Styner M, Zhu H. TWO-STAGE EMPIRICAL LIKELIHOOD FOR LONGITUDINAL NEUROIMAGING DATA. The Annals of Applied Statistics. 5: 1132-1158. PMID 21765885 DOI: 10.1214/11-Aoas480  0.37
2011 Marx CE, Bradford DW, Hamer RM, Naylor JC, Allen TB, Lieberman JA, Strauss JL, Kilts JD. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience. 191: 78-90. PMID 21756978 DOI: 10.1016/J.Neuroscience.2011.06.076  0.378
2011 Hermes E, Nasrallah H, Davis V, Meyer J, McEvoy J, Goff D, Davis S, Stroup TS, Swartz M, Lieberman J, Rosenheck R. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophrenia Research. 128: 166-70. PMID 21334853 DOI: 10.1016/J.Schres.2011.01.022  0.385
2011 Girgis RR, Phillips MR, Li X, Li K, Jiang H, Wu C, Duan N, Niu Y, Lieberman JA. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. The British Journal of Psychiatry : the Journal of Mental Science. 199: 281-8. PMID 21292928 DOI: 10.1192/Bjp.Bp.110.081471  0.325
2011 Wessels AM, Bies RR, Pollock BG, Schneider LS, Lieberman JA, Stroup S, Li CH, Coley K, Kirshner MM, Marder SR. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. Journal of Clinical Pharmacology. 51: 1587-91. PMID 21209243 DOI: 10.1177/0091270010387604  0.349
2011 Stauffer VL, Case M, Kinon BJ, Conley R, Ascher-Svanum H, Kollack-Walker S, Kane J, McEvoy J, Lieberman J. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Research. 187: 42-8. PMID 21168920 DOI: 10.1016/J.Psychres.2010.11.017  0.399
2011 Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biological Psychiatry. 69: 442-9. PMID 21145041 DOI: 10.1016/J.Biopsych.2010.09.052  0.323
2011 Girgis RR, Merrill DB, Vorel SR, Edward Kim, Kimberly Portland, You M, Pikalov A, Whitehead R, Lieberman JA. Aripiprazole versus haloperidol treatment in early-stage schizophrenia. Journal of Psychiatric Research. 45: 756-62. PMID 20937506 DOI: 10.1016/J.Jpsychires.2010.09.003  0.33
2011 Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. The Journal of Clinical Psychiatry. 72: 75-80. PMID 20868641 DOI: 10.4088/Jcp.09M05258Gre  0.345
2011 Caroff SN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, Campbell EC, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RS, Stroup TS, Lieberman JA. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. The Journal of Clinical Psychiatry. 72: 295-303. PMID 20816031 DOI: 10.4088/Jcp.09M05793Yel  0.355
2011 Souza RP, Rosa DV, Romano-Silva MA, Zhen M, Meltzer HY, Lieberman JA, Remington G, Kennedy JL, Wong AH. Lack of association of NALCN genetic variants with schizophrenia. Psychiatry Research. 185: 450-2. PMID 20674038 DOI: 10.1016/J.Psychres.2010.07.009  0.363
2011 McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI, Lieberman JA, Sullivan PF, van den Oord EJ. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Molecular Psychiatry. 16: 76-85. PMID 19721433 DOI: 10.1038/Mp.2009.89  0.326
2011 Lyon GJ, Abi-Dargham A, Moore H, Lieberman JA, Javitch JA, Sulzer D. Presynaptic regulation of dopamine transmission in schizophrenia. Schizophrenia Bulletin. 37: 108-17. PMID 19525353 DOI: 10.1093/Schbul/Sbp010  0.35
2011 Lieberman JA. Interview: In search of the pathophysiology and prevention of schizophrenia Neuropsychiatry. 1: 225-231. DOI: 10.2217/NPY.11.30  0.385
2011 Ballon JS, Girgis RR, Lieberman JA. Personalized Medicine for Schizophrenia Integrative Neuroscience and Personalized Medicine. DOI: 10.1093/acprof:oso/9780195393804.003.0006  0.394
2011 Dunbar G, Hosford D, Segreti A, Lieberman J. P.3.e.017 Effects of alpha7 nicotinic receptor agonist TC-5619 in cognitive dysfunction in schizophrenia European Neuropsychopharmacology. 21. DOI: 10.1016/S0924-977X(11)70849-5  0.366
2011 Geddes JR, Stroup TS, Lieberman JA. Comparative Efficacy and Effectiveness in the Drug Treatment of Schizophrenia Schizophrenia: Third Edition. 525-539. DOI: 10.1002/9781444327298.ch25  0.353
2010 Souza RP, Meltzer HY, Lieberman JA, Le Foll B, Kennedy JL. Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response. Human Psychopharmacology. 25: 582-5. PMID 20860064 DOI: 10.1002/Hup.1146  0.354
2010 Huang J, Perlis RH, Lee PH, Rush AJ, Fava M, Sachs GS, Lieberman J, Hamilton SP, Sullivan P, Sklar P, Purcell S, Smoller JW. Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. The American Journal of Psychiatry. 167: 1254-63. PMID 20713499 DOI: 10.1176/Appi.Ajp.2010.09091335  0.35
2010 Smith T, Weston C, Lieberman J. Schizophrenia (maintenance treatment). American Family Physician. 82: 338-9. PMID 20704164  0.395
2010 Zai CC, Manchia M, De Luca V, Tiwari AK, Squassina A, Zai GC, Strauss J, Shaikh SA, Freeman N, Meltzer HY, Lieberman J, Le Foll B, Kennedy JL. Association study of BDNF and DRD3 genes in schizophrenia diagnosis using matched case-control and family based study designs. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34: 1412-8. PMID 20667458 DOI: 10.1016/J.Pnpbp.2010.07.019  0.354
2010 El-Sayed M, Steen RG, Poe MD, Bethea TC, Gerig G, Lieberman J, Sikich L. Brain volumes in psychotic youth with schizophrenia and mood disorders. Journal of Psychiatry & Neuroscience : Jpn. 35: 229-36. PMID 20569649 DOI: 10.1503/Jpn.090051  0.419
2010 Gilmore JH, Kang C, Evans DD, Wolfe HM, Smith JK, Lieberman JA, Lin W, Hamer RM, Styner M, Gerig G. Prenatal and neonatal brain structure and white matter maturation in children at high risk for schizophrenia. The American Journal of Psychiatry. 167: 1083-91. PMID 20516153 DOI: 10.1176/Appi.Ajp.2010.09101492  0.323
2010 Findling RL, Johnson JL, McClellan J, Frazier JA, Vitiello B, Hamer RM, Lieberman JA, Ritz L, McNamara NK, Lingler J, Hlastala S, Pierson L, Puglia M, Maloney AE, Kaufman EM, et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. Journal of the American Academy of Child and Adolescent Psychiatry. 49: 583-94; quiz 632. PMID 20494268 DOI: 10.1016/J.Jaac.2010.03.013  0.357
2010 Hooper SR, Giuliano AJ, Youngstrom EA, Breiger D, Sikich L, Frazier JA, Findling RL, McClellan J, Hamer RM, Vitiello B, Lieberman JA. Neurocognition in early-onset schizophrenia and schizoaffective disorders. Journal of the American Academy of Child and Adolescent Psychiatry. 49: 52-60. PMID 20215926 DOI: 10.1016/J.Jaac.2009.11.001  0.315
2010 Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 13: 793-8. PMID 20196918 DOI: 10.1017/S1461145710000167  0.346
2010 Souza RP, Romano-Silva MA, Lieberman JA, Meltzer HY, MacNeil LT, Culotti JG, Kennedy JL, Wong AH. Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response. Journal of Psychiatric Research. 44: 700-6. PMID 20116071 DOI: 10.1016/J.Jpsychires.2010.01.002  0.351
2010 Glantz LA, Gilmore JH, Overstreet DH, Salimi K, Lieberman JA, Jarskog LF. Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression. Schizophrenia Research. 118: 292-9. PMID 20067857 DOI: 10.1016/J.Schres.2009.12.027  0.345
2010 Ballon JS, Lieberman JA. Advances in the Management of Treatment- Resistant Schizophrenia Focus. 8: 475-487. DOI: 10.1176/FOC.8.4.FOC475  0.309
2010 Scott Stroup T, Lieberman JA. Antipsychotic trials in schizophrenia: The CATIE project Antipsychotic Trials in Schizophrenia: the Catie Project. 1-312. DOI: 10.1017/CBO9780511712265  0.358
2010 Buchanan RW, Barch D, Csernansky J, Goff D, Gold J, Jarskog F, Javitt D, Keefe R, Lieberman J, McEvoy J, McMahon R, Marder S. MK-0777 FOR THE TREATMENT OF COGNITIVE IMPAIRMENTS IN PEOPLE WITH SCHIZOPHRENIA Schizophrenia Research. 117: 119. DOI: 10.1016/J.Schres.2010.02.053  0.436
2009 Souza RP, Tampakeras M, Basile V, Shinkai T, Rosa DV, Potkin S, Meltzer HY, Lieberman JA, Romano-Silva MA, Kennedy JL. Lack of association of GPX1 and MnSOD genes with symptom severity and response to clozapine treatment in schizophrenia subjects. Human Psychopharmacology. 24: 676-9. PMID 19946932 DOI: 10.1002/Hup.1076  0.323
2009 Salimi K, Jarskog LF, Lieberman JA. Antipsychotic drugs for first-episode schizophrenia: a comparative review. Cns Drugs. 23: 837-55. PMID 19739694 DOI: 10.2165/11314280-000000000-00000  0.363
2009 Rosenheck RA, Davis VG, Davis SM, Stroup S, McEvoy J, Swartz M, Lieberman J. Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. Schizophrenia Research. 113: 12-8. PMID 19545976 DOI: 10.1016/J.Schres.2009.06.002  0.336
2009 Smith TE, Weston CA, Lieberman JA. Schizophrenia (maintenance treatment). Bmj Clinical Evidence. 2009. PMID 19445748  0.344
2009 Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, Miller AL, Rosenheck RA, Hsiao JK. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research. 107: 1-12. PMID 19027269 DOI: 10.1016/J.Schres.2008.10.011  0.352
2009 Kleinman L, Lieberman J, Dube S, Mohs R, Zhao Y, Kinon B, Carpenter W, Harvey PD, Green MF, Keefe RS, Frank L, Bowman L, Revicki DA. Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. Schizophrenia Research. 107: 275-85. PMID 19013769 DOI: 10.1016/J.Schres.2008.10.002  0.379
2009 Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia XD, Gage A. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia Neuropsychopharmacology. 34: 1322-1329. PMID 19005465 DOI: 10.1038/Npp.2008.200  0.385
2009 van den Oord EJ, Adkins DE, McClay J, Lieberman J, Sullivan PF. A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophrenia Research. 107: 13-21. PMID 18930379 DOI: 10.1016/J.Schres.2008.09.009  0.325
2009 Thompson PM, Bartzokis G, Hayashi KM, Klunder AD, Lu PH, Edwards N, Hong MS, Yu M, Geaga JA, Toga AW, Charles C, Perkins DO, McEvoy J, Hamer RM, Tohen M, ... Lieberman JA, et al. Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cerebral Cortex (New York, N.Y. : 1991). 19: 1107-23. PMID 18842668 DOI: 10.1093/Cercor/Bhn152  0.32
2008 Morey RA, Mitchell TV, Inan S, Lieberman JA, Belger A. Neural correlates of automatic and controlled auditory processing in schizophrenia. The Journal of Neuropsychiatry and Clinical Neurosciences. 20: 419-30. PMID 19196926 DOI: 10.1176/Appi.Neuropsych.20.4.419  0.585
2008 Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, Aprille JR, Dwyer DS, Li XM, Mahadik SP, Duman RS, Porter JH, Modica-Napolitano JS, Newton SS, Csernansky JG. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacological Reviews. 60: 358-403. PMID 18922967 DOI: 10.1124/Pr.107.00107  0.348
2008 Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, ... ... Lieberman JA, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. The American Journal of Psychiatry. 165: 1420-31. PMID 18794207 DOI: 10.1176/Appi.Ajp.2008.08050756  0.376
2008 Swanson JW, Swartz MS, Van Dorn RA, Volavka J, Monahan J, Stroup TS, McEvoy JP, Wagner HR, Elbogen EB, Lieberman JA. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry : the Journal of Mental Science. 193: 37-43. PMID 18700216 DOI: 10.1192/Bjp.Bp.107.042630  0.381
2008 Lieberman JA, Javitch JA, Moore H. Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. The American Journal of Psychiatry. 165: 931-6. PMID 18676593 DOI: 10.1176/Appi.Ajp.2008.08050769  0.349
2008 Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophrenia Research. 103: 104-9. PMID 18534821 DOI: 10.1016/J.Schres.2008.04.023  0.356
2008 Souza RP, Romano-Silva MA, Lieberman JA, Meltzer HY, Wong AH, Kennedy JL. Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology. 200: 177-86. PMID 18500637 DOI: 10.1007/S00213-008-1193-9  0.392
2008 Lieberman JA, Drake RE, Sederer LI, Belger A, Keefe R, Perkins D, Stroup S. Science and recovery in schizophrenia. Psychiatric Services (Washington, D.C.). 59: 487-96. PMID 18451003 DOI: 10.1176/Ps.2008.59.5.487  0.593
2008 Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RS. Relationship of cognition and psychopathology to functional impairment in schizophrenia. The American Journal of Psychiatry. 165: 978-87. PMID 18450928 DOI: 10.1176/Appi.Ajp.2008.07111713  0.306
2008 Lewis S, Lieberman J. CATIE and CUtLASS: can we handle the truth? British Journal of Psychiatry. 192: 161-163. PMID 18310570 DOI: 10.1192/Bjp.Bp.107.037218  0.35
2008 Campbell DB, Lange LA, Skelly T, Lieberman J, Levitt P, Sullivan PF. Association of RGS2 and RGS5 variants with schizophrenia symptom severity. Schizophrenia Research. 101: 67-75. PMID 18262772 DOI: 10.1016/J.Schres.2008.01.006  0.464
2008 Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophrenia Research. 101: 273-86. PMID 18258416 DOI: 10.1016/J.Schres.2007.12.487  0.309
2008 Resnick SG, Rosenheck RA, Canive JM, De Souza C, Stroup TS, McEvoy J, Davis S, Keefe RS, Swartz M, Lieberman J. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. The Journal of Behavioral Health Services & Research. 35: 215-25. PMID 18246429 DOI: 10.1007/S11414-007-9101-3  0.407
2008 Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, Miller DD, McGee M, Khan A, Canive JM, Davis SM, Hsiao JK, Lieberman JA. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophrenia Research. 100: 39-52. PMID 18191383 DOI: 10.1016/J.Schres.2007.11.034  0.328
2008 Campbell DB, Ebert PJ, Skelly T, Stroup TS, Lieberman J, Levitt P, Sullivan PF. Ethnic Stratification of the Association of RGS4 Variants with Antipsychotic Treatment Response in Schizophrenia Biological Psychiatry. 63: 32-41. PMID 17588543 DOI: 10.1016/J.Biopsych.2007.04.018  0.472
2008 Sevy S, Robinson DG, Holloway S, Alvir JM, Woerner MG, Bilder R, Goldman R, Lieberman J, Kane J. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder Acta Psychiatrica Scandinavica. 104: 367-374. DOI: 10.1111/J.1600-0447.2001.00452.X  0.468
2008 Stroup S, Lieberman J, McEvoy J, Swartz M, Davis S, Rosenheck R, Keefe R. Findings Of Phase 3 Of The Catie Schizophrenia Trial Schizophrenia Research. 102: 34-35. DOI: 10.1016/S0920-9964(08)70109-9  0.443
2008 Kennedy JL, Mueller D, Zai C, Desouza R, Tiwari A, Meltzer H, Lieberman J. PHARMACOGENETICS OF SCHIZOPHRENIA: TARDIVE DYSKINESIA AND WEIGHT GAIN Schizophrenia Research. 102: 34. DOI: 10.1016/S0920-9964(08)70107-5  0.347
2007 Renou J, De Luca V, Zai CC, Bulgin N, Remington G, Meltzer HY, Lieberman JA, Le Foll B, Kennedy JL. Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia. Molecular Psychiatry. 12: 1058-60. PMID 18043709 DOI: 10.1038/Sj.Mp.4002092  0.356
2007 Lieberman JA. Neuroprotection: a new strategy in the treatment of schizophrenia. Neurobiological basis of neurodegeneration and neuroprotection Cns Spectrums. 12: 4-6. PMID 17934388  0.368
2007 Frazier JA, McClellan J, Findling RL, Vitiello B, Anderson R, Zablotsky B, Williams E, McNamara NK, Jackson JA, Ritz L, Hlastala SA, Pierson L, Varley JA, Puglia M, Maloney AE, ... Lieberman JA, et al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics. Journal of the American Academy of Child and Adolescent Psychiatry. 46: 979-88. PMID 17667477 DOI: 10.1097/Chi.0B013E31807083Fd  0.359
2007 McClellan J, Sikich L, Findling RL, Frazier JA, Vitiello B, Hlastala SA, Williams E, Ambler D, Hunt-Harrison T, Maloney AE, Ritz L, Anderson R, Hamer RM, Lieberman JA. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. Journal of the American Academy of Child and Adolescent Psychiatry. 46: 969-78. PMID 17667476 DOI: 10.1097/Chi.0B013E3180691779  0.361
2007 Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophrenia Bulletin. 33: 1120-30. PMID 17641146 DOI: 10.1093/Schbul/Sbm083  0.31
2007 Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, ... Lieberman JA, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry. 64: 633-47. PMID 17548746 DOI: 10.1001/Archpsyc.64.6.633  0.317
2007 Pinheiro AP, Keefe RS, Skelly T, Olarte M, Leviel K, Lange LA, Lange EM, Stroup TS, Lieberman J, Sullivan PF. AKT1 and neurocognition in schizophrenia. The Australian and New Zealand Journal of Psychiatry. 41: 169-77. PMID 17464696 DOI: 10.1080/00048670601109956  0.49
2007 Lieberman JA, Perkins DO, Jarskog LF. Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. Cns Spectrums. 12: 1-13; quiz 14. PMID 17329984 DOI: 10.1017/S1092852900025906  0.405
2007 Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American Journal of Psychiatry. 164: 428-36. PMID 17329467 DOI: 10.1176/Ajp.2007.164.3.428  0.381
2007 Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. The American Journal of Psychiatry. 164: 415-27. PMID 17329466 DOI: 10.1176/Ajp.2007.164.3.415  0.396
2007 Lieberman JA, First MB. Renaming schizophrenia British Medical Journal. 334: 108. PMID 17235058 DOI: 10.1136/bmj.39057.662373.80  0.399
2007 Sullivan PF, Keefe RS, Lange LA, Lange EM, Stroup TS, Lieberman J, Maness PF. NCAM1 and neurocognition in schizophrenia. Biological Psychiatry. 61: 902-10. PMID 17161382 DOI: 10.1016/J.Biopsych.2006.07.036  0.423
2007 Jarskog LF, Miyamoto S, Lieberman JA. Schizophrenia: new pathological insights and therapies. Annual Review of Medicine. 58: 49-61. PMID 16903799 DOI: 10.1146/Annurev.Med.58.060904.084114  0.408
2007 Lieberman J, Corcoran C. The impossible dream: can psychiatry prevent psychosis? Early Intervention in Psychiatry. 1: 219-221. DOI: 10.1111/J.1751-7893.2007.00031.X  0.35
2007 Lieberman JA, Buckley PF, Perkins DO. Neuroprotection: A New Strategy in the Treatment of Schizophrenia Cns Spectrums. 12: 1-16. DOI: 10.1017/S1092852900026328  0.422
2006 Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. The American Journal of Psychiatry. 163: 2080-9. PMID 17151158 DOI: 10.1176/Ajp.2006.163.12.2080  0.458
2006 Hoptman MJ, Volavka J, Czobor P, Gerig G, Chakos M, Blocher J, Citrome LL, Sheitman B, Lindenmayer JP, Lieberman JA, Bilder RM. Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder. The Journal of Neuropsychiatry and Clinical Neurosciences. 18: 509-15. PMID 17135376 DOI: 10.1176/Appi.Neuropsych.18.4.509  0.328
2006 Lieberman JA. Neurobiology and the natural history of schizophrenia The Journal of Clinical Psychiatry. 67. PMID 17107237  0.389
2006 van der Stelt O, Lieberman JA, Belger A. Attentional modulation of early-stage visual processing in schizophrenia. Brain Research. 1125: 194-8. PMID 17087921 DOI: 10.1016/J.Brainres.2006.09.099  0.594
2006 Jarskog LF, Lieberman JA. Neuroprotection in schizophrenia Journal of Clinical Psychiatry. 67. PMID 17081076 DOI: 10.4088/Jcp.0906E09  0.356
2006 Lieberman JA. Comparative effectiveness of antipsychotic drugs: A commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Archives of General Psychiatry. 63: 1069-1072. PMID 17015808 DOI: 10.1001/Archpsyc.63.10.1069  0.304
2006 Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. The Journal of Clinical Psychiatry. 67: 1093-103. PMID 16889453 DOI: 10.4088/Jcp.V67N0712  0.382
2006 Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophrenia Research. 86: 234-43. PMID 16887334 DOI: 10.1016/J.Schres.2006.06.021  0.344
2006 Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research. 86: 15-22. PMID 16884895 DOI: 10.1016/J.Schres.2006.06.026  0.332
2006 Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, McGee M, Miller DD, Reimherr F, Khan A, Cañive JM, Lieberman JA. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatric Services (Washington, D.C.). 57: 1110-6. PMID 16870961 DOI: 10.1176/Ps.2006.57.8.1110  0.364
2006 Chwastiak LA, Rosenheck RA, McEvoy JP, Keefe RS, Swartz MS, Lieberman JA. Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. Psychiatric Services (Washington, D.C.). 57: 1102-9. PMID 16870960 DOI: 10.1176/Ps.2006.57.8.1102  0.345
2006 Lieberman JA, Jarskog LF, Malaspina D. Preventing clinical deterioration in the course of schizophrenia: The potential for neuroprotection Journal of Clinical Psychiatry. 67: 983-990. PMID 16848659 DOI: 10.4088/Jcp.V67N0616  0.365
2006 Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. The British Journal of Psychiatry : the Journal of Mental Science. 188: 510-8. PMID 16738340 DOI: 10.1192/Bjp.188.6.510  0.352
2006 Swanson JW, Swartz MS, Van Dorn RA, Elbogen EB, Wagner HR, Rosenheck RA, Stroup TS, McEvoy JP, Lieberman JA. A national study of violent behavior in persons with schizophrenia. Archives of General Psychiatry. 63: 490-9. PMID 16651506 DOI: 10.1001/Archpsyc.63.5.490  0.324
2006 Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller DD, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, ... ... Lieberman JA, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 2033-46. PMID 16641947 DOI: 10.1038/Sj.Npp.1301072  0.352
2006 Lieberman JA, Malaspina D, Jarskog LF. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. Cns Spectrums. 11: suppl 1-13; quiz sup. PMID 16641837  0.392
2006 Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. The American Journal of Psychiatry. 163: 611-22. PMID 16585435 DOI: 10.1176/Appi.Ajp.163.4.611  0.415
2006 McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. The American Journal of Psychiatry. 163: 600-10. PMID 16585434 DOI: 10.1176/Appi.Ajp.163.4.600  0.397
2006 Rosenheck R, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D, Stroup S, Hsiao JK, Lieberman J. Barriers to employment for people with schizophrenia. The American Journal of Psychiatry. 163: 411-7. PMID 16513861 DOI: 10.1176/Appi.Ajp.163.3.411  0.476
2006 Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ, Altamura AC, Andreasen N, Barnes TRE, Beckmann H, Ciprian-Ollivier J, Crow T, David A, Davidson M, Deakin B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: Long-term treatment of schizophrenia World Journal of Biological Psychiatry. 7: 5-40. PMID 16509050 DOI: 10.1080/15622970500483177  0.365
2006 Umbricht DS, Bates JA, Lieberman JA, Kane JM, Javitt DC. Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biological Psychiatry. 59: 762-72. PMID 16497277 DOI: 10.1016/J.Biopsych.2005.08.030  0.31
2006 Bilder RM, Reiter G, Bates J, Lencz T, Szeszko P, Goldman RS, Robinson D, Lieberman JA, Kane JM. Cognitive development in schizophrenia: follow-back from the first episode. Journal of Clinical and Experimental Neuropsychology. 28: 270-82. PMID 16484098 DOI: 10.1080/13803390500360554  0.346
2006 Merrill DB, Ahmari SE, Bradford JM, Lieberman JA. Myocarditis during clozapine treatment. The American Journal of Psychiatry. 163: 204-8. PMID 16449471 DOI: 10.1176/Appi.Ajp.163.2.204  0.328
2006 Lieberman JA, Hsiao JK. Interpreting the results of the CATIE study [1] Psychiatric Services. 57: 139. PMID 16399980 DOI: 10.1176/Appi.Ps.57.1.139  0.363
2006 Marx CE, Stevens RD, Shampine LJ, Uzunova V, Trost WT, Butterfield MI, Massing MW, Hamer RM, Morrow AL, Lieberman JA. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 1249-63. PMID 16319920 DOI: 10.1038/Sj.Npp.1300952  0.332
2006 Rosenheck R, Stroup S, Keefe RS, McEvoy J, Swartz M, Perkins D, Hsiao J, Shumway M, Lieberman J. Measuring outcome priorities and preferences in people with schizophrenia. The British Journal of Psychiatry : the Journal of Mental Science. 187: 529-36. PMID 16319405 DOI: 10.1192/Bjp.187.6.529  0.386
2006 Lieberman JA. Neurobiology and the Natural History of Schizophrenia The Journal of Clinical Psychiatry. 67: e11. DOI: 10.4088/Jcp.1006E14  0.389
2006 Rappard F, Loebel A, Warrington L, Siu C, Lieberman J. P.3.a.047 Remission in schizophrenia: a comparison of 2 dose regimens of ziprasidone versus haloperidol in a 40-week core and 3-year double-blind continuation study European Neuropsychopharmacology. 16: S390. DOI: 10.1016/S0924-977X(06)70476-X  0.323
2006 Perkins D, Gu H, Zipursky R, Gerig G, Lieberman J. TC18C MRI OF BRAIN VOLUMES AT THE PRODROME AND FIRST EPISODE STAGES OF SCHIZOPHRENIA Schizophrenia Research. 86: S59. DOI: 10.1016/S0920-9964(06)70176-1  0.316
2005 Nemeroff CB, Lieberman JA, Weiden PJ, Harvey PD, Newcomer JW, Schatzberg AF, Kilts CD, Daniel DG. From clinical research to clinical practice: a 4-year review of ziprasidone. Cns Spectrums. 10: 1-20. PMID 16381088 DOI: 10.1017/S1092852900019842  0.347
2005 Hoptman MJ, Volavka J, Weiss EM, Czobor P, Szeszko PR, Gerig G, Chakos M, Blocher J, Citrome LL, Lindenmayer JP, Sheitman B, Lieberman JA, Bilder RM. Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder. Psychiatry Research. 140: 133-45. PMID 16253482 DOI: 10.1016/J.Pscychresns.2005.07.004  0.33
2005 Gunduz-Bruce H, McMeniman M, Robinson DG, Woerner MG, Kane JM, Schooler NR, Lieberman JA. Duration of untreated psychosis and time to treatment response for delusions and hallucinations. The American Journal of Psychiatry. 162: 1966-9. PMID 16199847 DOI: 10.1176/Appi.Ajp.162.10.1966  0.336
2005 Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S, Lieberman JA. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research. 80: 45-53. PMID 16198088 DOI: 10.1016/J.Schres.2005.08.010  0.348
2005 Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, Kim S, Keefe R, Manschreck T, McEvoy J, Lieberman J. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research. 80: 1-8. PMID 16182516 DOI: 10.1016/J.Schres.2005.08.007  0.411
2005 Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ, Altamura AC, Andreasen N, Barnes TRE, Beckmann H, Ciprian-Ollivier J, Crow T, David A, Davidson M, Deakin B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: Acute treatment of schizophrenia World Journal of Biological Psychiatry. 6: 132-191. PMID 16173147 DOI: 10.1080/15622970510030090  0.48
2005 Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, Swartz MS, Keefe RS, Rosenheck RA, Stroup TS, Lieberman JA. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research. 80: 33-43. PMID 16171976 DOI: 10.1016/J.Schres.2005.07.034  0.388
2005 McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research. 80: 19-32. PMID 16137860 DOI: 10.1016/J.Schres.2005.07.014  0.347
2005 Pinkham A, Penn D, Wangelin B, Perkins D, Gerig G, Gu H, Lieberman J. Facial emotion perception and fusiform gyrus volume in first episode schizophrenia. Schizophrenia Research. 79: 341-3. PMID 16125902 DOI: 10.1016/J.Schres.2005.07.012  0.397
2005 Strakowski SM, Johnson JL, Delbello MP, Hamer RM, Green AI, Tohen M, Lieberman JA, Glick I, Patel JK. Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophrenia Research. 78: 161-9. PMID 15950436 DOI: 10.1016/J.Schres.2005.04.017  0.423
2005 van der Stelt O, Lieberman JA, Belger A. Auditory P300 in high-risk, recent-onset and chronic schizophrenia. Schizophrenia Research. 77: 309-20. PMID 15944141 DOI: 10.1016/J.Schres.2005.04.024  0.626
2005 Jarskog LF, Glantz LA, Gilmore JH, Lieberman JA. Apoptotic mechanisms in the pathophysiology of schizophrenia Progress in Neuro-Psychopharmacology and Biological Psychiatry. 29: 846-858. PMID 15908096 DOI: 10.1016/J.Pnpbp.2005.03.010  0.345
2005 Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry. 62: 361-70. PMID 15809403 DOI: 10.1001/Archpsyc.62.4.361  0.326
2005 Styner M, Lieberman JA, McClure RK, Weinberger DR, Jones DW, Gerig G. Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors. Proceedings of the National Academy of Sciences of the United States of America. 102: 4872-7. PMID 15772166 DOI: 10.1073/Pnas.0501117102  0.314
2005 Morey RA, Inan S, Mitchell TV, Perkins DO, Lieberman JA, Belger A. Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Archives of General Psychiatry. 62: 254-62. PMID 15753238 DOI: 10.1001/Archpsyc.62.3.254  0.532
2005 De Luca V, Vincent JB, Müller DJ, Hwang R, Shinkai T, Volavka J, Czobor P, Sheitman BB, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA, Kennedy JL. Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. Pharmacological Research. 51: 381-4. PMID 15683753 DOI: 10.1016/J.Phrs.2004.10.013  0.341
2005 Chakos MH, Schobel SA, Gu H, Gerig G, Bradford D, Charles C, Lieberman JA. Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. The British Journal of Psychiatry : the Journal of Mental Science. 186: 26-31. PMID 15630120 DOI: 10.1192/Bjp.186.1.26  0.354
2005 Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry. 10: 79-104. PMID 15289815 DOI: 10.1038/Sj.Mp.4001556  0.336
2004 Stroup TS, McEvoy JP, Lieberman JA. Revised PORT recommendations Schizophrenia Bulletin. 30: 609-611. PMID 15631251 DOI: 10.1093/Oxfordjournals.Schbul.A007106  0.322
2004 van der Stelt O, Belger A, Lieberman JA. Macroscopic fast neuronal oscillations and synchrony in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 101: 17567-8. PMID 15601768 DOI: 10.1073/Pnas.0407688101  0.608
2004 Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, et al. Physical health monitoring of patients with schizophrenia. The American Journal of Psychiatry. 161: 1334-49. PMID 15285957 DOI: 10.1176/Appi.Ajp.161.8.1334  0.338
2004 Strous RD, Alvir JM, Robinson D, Gal G, Sheitman B, Chakos M, Lieberman JA. Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects. Schizophrenia Bulletin. 30: 265-78. PMID 15279045 DOI: 10.1093/Oxfordjournals.Schbul.A007077  0.365
2004 Perkins DO, Lieberman JA, Gu H, Tohen M, McEvoy J, Green AI, Zipursky RB, Strakowski SM, Sharma T, Kahn RS, Gur R, Tollefson G. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders British Journal of Psychiatry. 185: 18-24. PMID 15231551 DOI: 10.1192/Bjp.185.1.18  0.378
2004 Volavka J, Czobor P, Nolan K, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Lieberman JA. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. Journal of Clinical Psychopharmacology. 24: 225-8. PMID 15206671 DOI: 10.1097/01.Jcp.0000117424.05703.29  0.355
2004 Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. The Journal of Clinical Psychiatry. 65: 551-6. PMID 15119920 DOI: 10.4088/Jcp.V65N0416  0.385
2004 Alamy SS, Jarskog LF, Sheitman BB, Lieberman JA. Secretin in a patient with treatment-resistant schizophrenia and prominent autistic features Schizophrenia Research. 66: 183-186. PMID 15061252 DOI: 10.1016/J.Schres.2003.07.003  0.377
2004 Sheitman BB, Knable MB, Jarskog LF, Chakos M, Boyce LH, Early J, Lieberman JA. Secretin for refractory schizophrenia. Schizophrenia Research. 66: 177-81. PMID 15061251 DOI: 10.1016/S0920-9964(03)00068-9  0.4
2004 Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophrenia Research. 66: 125-35. PMID 15061244 DOI: 10.1016/J.Schres.2003.08.001  0.303
2004 Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, McIntyre JS, Charles SC, Altshuler K, Cook I, Cross CD, Mellman L, Moench LA, Norquist G, et al. Practice Guideline for the Treatment of Partients with Schizophrenia, Second Edition American Journal of Psychiatry. 161: i-iv+1-56. PMID 15000267  0.358
2004 van der Stelt O, Frye J, Lieberman JA, Belger A. Impaired P3 generation reflects high-level and progressive neurocognitive dysfunction in schizophrenia. Archives of General Psychiatry. 61: 237-48. PMID 14993111 DOI: 10.1001/Archpsyc.61.3.237  0.604
2004 Volavka J, Czobor P, Sheitman B, Lindenmayer J, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder Focus. 2: 59-67. DOI: 10.1176/FOC.2.1.59  0.387
2003 Miyamoto S, LaMantia AS, Duncan GE, Sullivan P, Gilmore JH, Lieberman JA. Recent advances in the neurobiology of schizophrenia. Molecular Interventions. 3: 27-39. PMID 14993436 DOI: 10.1124/Mi.3.1.27  0.399
2003 Bradford DW, Perkins DO, Lieberman JA. Pharmacological Management of First-Episode Schizophrenia and Related Nonaffective Psychoses Drugs. 63: 2265-2283. PMID 14524730 DOI: 10.2165/00003495-200363210-00001  0.425
2003 Szeszko PR, Gunning-Dixon F, Goldman RS, Bates J, Ashtari M, Snyder PJ, Lieberman JA, Bilder RM. Lack of normal association between cerebellar volume and neuropsychological functions in first-episode schizophrenia. The American Journal of Psychiatry. 160: 1884-7. PMID 14514506 DOI: 10.1176/Appi.Ajp.160.10.1884  0.362
2003 Lieberman JA, Stroup TS. Schizophrenia, VI: Treatments The American Journal of Psychiatry. 160: 1748. PMID 14514482 DOI: 10.1176/Appi.Ajp.160.10.1748  0.393
2003 Woerner MG, Robinson DG, Alvir JM, Sheitman BB, Lieberman JA, Kane JM. Clozapine as a first treatment for schizophrenia. The American Journal of Psychiatry. 160: 1514-6. PMID 12900316 DOI: 10.1176/Appi.Ajp.160.8.1514  0.406
2003 Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. The American Journal of Psychiatry. 160: 1396-404. PMID 12900300 DOI: 10.1176/Appi.Ajp.160.8.1396  0.344
2003 Pinkham AE, Penn DL, Perkins DO, Lieberman J. Implications for the neural basis of social cognition for the study of schizophrenia. The American Journal of Psychiatry. 160: 815-24. PMID 12727681 DOI: 10.1176/Appi.Ajp.160.5.815  0.401
2003 Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, Ji Z, Koch G, Hamer RM. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 995-1003. PMID 12700715 DOI: 10.1038/Sj.Npp.1300157  0.366
2003 Boteva K, Lieberman J. Reconsidering the classification of schizophrenia and manic depressive illness--a critical analysis and new conceptual model. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 4: 81-92. PMID 12692779 DOI: 10.3109/15622970309167956  0.32
2003 Boteva K, Lieberman J. Reconsidering the classification of schizophrenia and manic depressive illness--a critical analysis and new conceptual model. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 4: 81-92. PMID 12692779 DOI: 10.3109/15622970309167956  0.32
2003 Szeszko PR, Gunning-Dixon F, Ashtari M, Snyder PJ, Lieberman JA, Bilder RM. Reversed cerebellar asymmetry in men with first-episode schizophrenia. Biological Psychiatry. 53: 450-9. PMID 12614998 DOI: 10.1016/S0006-3223(02)01529-9  0.392
2003 Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. The American Journal of Psychiatry. 160: 290-6. PMID 12562575 DOI: 10.1176/Appi.Ajp.160.2.290  0.35
2003 McClure RK, Lieberman JA. Neurodevelopmental and neurodegenerative hypotheses of schizophrenia: A review and critique Current Opinion in Psychiatry. 16: S15-S28. DOI: 10.1097/00001504-200304002-00004  0.381
2003 Kahn R, Lieberman J, Charles C, Sharma T, Zipursky R, Gur R, Tohen M, Green A, McEvoy J, Perkins D, Hamer R, Nemeroff C, Rothschild A, Kuldau J, Strakowski S, et al. P.2.131 Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia European Neuropsychopharmacology. 13: S337. DOI: 10.1016/S0924-977X(03)92084-0  0.37
2003 Mueller D, Hwang R, Volavka J, Lieberman J, Kennedy J. No association between the COMT VAL158MET polymorphism and antipsychotic response in schizophrenia Schizophrenia Research. 60: 86. DOI: 10.1016/S0920-9964(03)80643-6  0.375
2003 Centorrino F, Hamer R, Tohen M, Lieberman J. Drug attitudes and treatment adherence in a clinical trial comparing haloperidol and olanzapine in first episode schizophrenia Schizophrenia Research. 60: 277. DOI: 10.1016/S0920-9964(03)80442-5  0.351
2003 Umbricht D, Javitt D, Bates J, Kane J, Lieberman J. Deficits in mismatch negativity in schizophrenia: Predictor of outcome or result of illness progression? Schizophrenia Research. 60: 262. DOI: 10.1016/S0920-9964(03)80401-2  0.36
2002 Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. The Journal of Clinical Psychiatry. 63: 931-5. PMID 12416603 DOI: 10.4088/JCP.V63N1011  0.393
2002 Goldstein RZ, Giovannetti T, Schullery M, Zuffante PA, Lieberman JA, Robinson DG, Barr WB, Bilder RM. Neurocognitive correlates of response to treatment in formal thought disorder in patients with first-episode schizophrenia. Neuropsychiatry, Neuropsychology, and Behavioral Neurology. 15: 88-98. PMID 12050471  0.34
2002 Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Lieberman J, Schooler NR. The Mount Sinai Conference on the Pharmacotherapy of Schizophrenia Schizophrenia Bulletin. 28: 5-16. PMID 12047022 DOI: 10.1093/Oxfordjournals.Schbul.A006926  0.494
2002 Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. The American Journal of Psychiatry. 159: 1018-28. PMID 12042192 DOI: 10.1176/appi.ajp.159.6.1018  0.336
2002 Gunduz H, Wu H, Ashtari M, Bogerts B, Crandall D, Robinson DG, Alvir J, Lieberman J, Kane J, Bilder R. Basal ganglia volumes in first-episode schizophrenia and healthy comparison subjects. Biological Psychiatry. 51: 801-8. PMID 12007454 DOI: 10.1016/S0006-3223(01)01345-2  0.479
2002 Lieberman J, Stroup S, Schneider L. Prevention of relapse in schizophrenia. The New England Journal of Medicine. 346: 1412-3; author reply. PMID 11987324  0.396
2002 Curtin F, Stalman SLP, Lieberman J, Schneider L, Csernansky JG, Mahmoud R. Prevention of relapse in schizophrenia [2] (multiple letters) New England Journal of Medicine. 346: 1412-1413. PMID 11987323 DOI: 10.1056/Nejm200205023461816  0.488
2002 Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. The American Journal of Psychiatry. 159: 255-62. PMID 11823268 DOI: 10.1176/Appi.Ajp.159.2.255  0.386
2002 Lindenmayer JP, Volavka J, Lieberman J, Sheitman B, Citrome L, Chakos M, Czobor P, Parker B, Iskander A. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. Journal of Clinical Psychopharmacology. 21: 448-53. PMID 11476131 DOI: 10.1097/00004714-200108000-00014  0.486
2002 Lieberman J, Eure T, Eure A. Sensitization in the pathogenesis and natural history of schizophrenia European Neuropsychopharmacology. 12: 114. DOI: 10.1016/S0924-977X(02)80050-5  0.38
2001 Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biological Psychiatry. 50: 884-97. PMID 11743943 DOI: 10.1016/S0006-3223(01)01303-8  0.634
2001 Sevy S, Robinson DG, Holloway S, Alvir JM, Woerner MG, Bilder R, Goldman R, Lieberman J, Kane J. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder Acta Psychiatrica Scandinavica. 104: 367-374. PMID 11722318 DOI: 10.1034/J.1600-0447.2001.00452.X  0.472
2001 Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, McEvoy J, Cooper TB, Chakos M, Lieberman JA. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatric Services (Washington, D.C.). 52: 1510-4. PMID 11684748 DOI: 10.1176/APPI.PS.52.11.1510  0.409
2001 Strous RD, Pollack S, Robinson D, Sheitman B, Lieberman JA. Seasonal admission patterns in first episode psychosis, chronic schizophrenia, and nonschizophrenic psychoses. The Journal of Nervous and Mental Disease. 189: 642-4. PMID 11580010 DOI: 10.1097/00005053-200109000-00012  0.356
2001 Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials American Journal of Psychiatry. 158: 518-526. PMID 11282684 DOI: 10.1176/Appi.Ajp.158.4.518  0.454
2000 Javitt DC, Shelley AM, Silipo G, Lieberman JA. Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern. Archives of General Psychiatry. 57: 1131-7. PMID 11115326 DOI: 10.1001/Archpsyc.57.12.1131  0.304
2000 Jarskog LF, Gilmore JH, Selinger ES, Lieberman JA. Cortical Bcl-2 protein expression and apoptotic regulation in schizophrenia Biological Psychiatry. 48: 641-650. PMID 11032975 DOI: 10.1016/S0006-3223(00)00988-4  0.339
2000 Perkins DO, Leserman J, Jarskog LF, Graham K, Kazmer J, Lieberman JA. Characterizing and dating the onset of symptoms in psychotic illness: The Symptom Onset in Schizophrenia (SOS) inventory Schizophrenia Research. 44: 1-10. PMID 10867307 DOI: 10.1016/S0920-9964(99)00161-9  0.356
2000 Gunduz H, Woerner MG, Alvir JM, Degreef G, Lieberman JA. Obstetric complications in schizophrenia, schizoaffective disorder and normal comparison subjects. Schizophrenia Research. 40: 237-43. PMID 10638862 DOI: 10.1016/S0920-9964(99)00054-7  0.39
2000 Mohr P, Volavka J, Lieberman J, Czobor P, McEvoy J, Lindenmayer J, Citrome L, Sheitman B. FC09.05 Clozapine, olanzapine, risperidone, and haloperidol in refractory schizophrenia European Psychiatry. 15: 284s-284s. DOI: 10.1016/S0924-9338(00)94238-X  0.407
2000 Lewis DA, Lieberman JA. Catching Up on Schizophrenia Neuron. 28: 325-334. DOI: 10.1016/S0896-6273(00)00111-2  0.399
2000 Chakos M, Charles C, Silva S, Sheitman B, Schobel S, Bradford D, Lieberman J. 84. Clinical correlates of structural brain abnormalities in schizophrenia Biological Psychiatry. 47: S25-S26. DOI: 10.1016/S0006-3223(00)00346-2  0.329
1999 Umbricht D, Javitt D, Novak G, Bates J, Pollack S, Lieberman J, Kane J. Effects of risperidone on auditory event-related potentials in schizophrenia. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 2: 299-304. PMID 11285146 DOI: 10.1017/S1461145799001595  0.434
1999 Bilder RM, Wu H, Bogerts B, Ashtari M, Robinson D, Woerner M, Lieberman JA, Degreef G. Cerebral volume asymmetries in schizophrenia and mood disorders: a quantitative magnetic resonance imaging study. International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology. 34: 197-205. PMID 10610044 DOI: 10.1016/S0167-8760(99)00077-X  0.349
1999 Yui K, Goto K, Ikemoto S, Ishiguro T, Angrist B, Duncan GE, Sheitman BB, Lieberman JA, Bracha SH, Ali SF. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. Molecular Psychiatry. 4: 512-23. PMID 10578232 DOI: 10.1038/Sj.Mp.4000575  0.388
1999 Duncan GE, Zorn S, Lieberman JA. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Molecular Psychiatry. 4: 418-28. PMID 10523814 DOI: 10.1038/Sj.Mp.4000581  0.309
1999 Lieberman JA. Schizophrenia: Comments on genes, development, risk factors, phenotype, and course Biological Psychiatry. 46: 869-870. PMID 10509169 DOI: 10.1016/S0006-3223(99)00214-0  0.322
1999 Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective Biological Psychiatry. 46: 729-739. PMID 10494440 DOI: 10.1016/S0006-3223(99)00147-X  0.4
1999 Lieberman JA. Searching for the neuropathology of schizophrenia: Neuroimaging strategies and findings American Journal of Psychiatry. 156: 1133-1136. PMID 10450250  0.38
1999 Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis Schizophrenia Bulletin. 25: 201-222. PMID 10416727 DOI: 10.1093/Oxfordjournals.Schbul.A033374  0.393
1999 Alvir JM, Woerner MG, Gunduz H, Degreef G, Lieberman JA. Obstetric complications predict treatment response in first-episode schizophrenia. Psychological Medicine. 29: 621-7. PMID 10405083 DOI: 10.1017/S0033291799008363  0.421
1999 Robinson DG, Woerner MG, Alvir JMJ, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder American Journal of Psychiatry. 156: 544-549. PMID 10200732 DOI: 10.1176/Ajp.156.4.544  0.369
1999 Robinson D, Woerner MG, Alvir JMJ, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder Archives of General Psychiatry. 56: 241-247. PMID 10078501 DOI: 10.1001/Archpsyc.56.3.241  0.365
1999 Chakos MH, Shirakawa O, Lieberman J, Lee H, Bilder R, Tamminga CA. Striatal enlargement in rats chronically treated with neuroleptic. Biological Psychiatry. 44: 675-84. PMID 9798070 DOI: 10.1016/S0006-3223(98)00029-8  0.323
1998 Umbricht D, Javitt D, Novak G, Bates J, Pollack S, Lieberman J, Kane J. Effects of clozapine on auditory event-related potentials in schizophrenia. Biological Psychiatry. 44: 716-25. PMID 9798075 DOI: 10.1016/S0006-3223(97)00524-6  0.456
1998 Sheitman BB, Lieberman JA. The natural history and pathophysiology of treatment resistant schizophrenia Journal of Psychiatric Research. 32: 143-150. PMID 9793867 DOI: 10.1016/S0022-3956(97)00052-6  0.391
1998 Anderson C, Chakos M, Mailman R, Lieberman J. Emerging roles for novel antipsychotic medications in the treatment of schizophrenia Psychiatric Clinics of North America. 21: 151-179. PMID 9551495 DOI: 10.1016/S0193-953X(05)70365-8  0.511
1998 Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics Journal of Clinical Psychiatry. 59: 69-75. PMID 9501888 DOI: 10.1016/S0920-9964(97)82764-8  0.394
1998 Lieberman JA. Pathophysiology in the clinical course of schizophrenia International Clinical Psychopharmacology. 13: S3-S6. DOI: 10.1097/00004850-199801001-00002  0.364
1998 Grube B, Goldman R, Alvir J, Bergman A, Bilder R, Lieberman J. 379. Symptom dimensions in first-episode schizophrenia: A longitudinal, confirmatory factor analytic study Biological Psychiatry. 43: S114. DOI: 10.1016/S0006-3223(98)90827-7  0.347
1998 Goldman R, Bilder R, Pappadopulos E, Reiter G, Alvir J, Robinson D, Lieberman J. 35. Neuropsychological prediction of functional outcome in first-episode schizophrenia Biological Psychiatry. 43: S11. DOI: 10.1016/S0006-3223(98)90483-8  0.324
1998 Bradford DW, Chakos MH, Sheitman BB, Lieberman JA. Atypical antipsychotic drugs in treatment-refractory schizophrenia Psychiatric Annals. 28: 618-626.  0.373
1997 Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: Deficits and dysfunction in neuronal regulation and plasticity Neuropsychopharmacology. 17: 205-229. PMID 9326746 DOI: 10.1016/S0893-133X(97)00045-6  0.416
1997 Koreen AR, Lieberman JA, Alvir J, Chakos M. The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls Neuropsychopharmacology. 16: 61-68. PMID 8981389 DOI: 10.1016/0920-9964(95)95480-W  0.434
1997 Gilmore JH, Sikich L, Lieberman JA. Neuroimaging, neurodevelopment, and schizophrenia Child and Adolescent Psychiatric Clinics of North America. 6: 325-341. DOI: 10.1016/S1056-4993(18)30307-9  0.397
1997 Waltrip RW, Lieberman J, Robinson D, Bilder RM, Alvir JM, King LR, Summerfelt A, Rubin SA, Carbone KM. First episode schizophrenia and borna disease virus Schizophrenia Research. 24: 261. DOI: 10.1016/S0920-9964(97)82754-5  0.435
1997 Gunduz H, Woerner MG, Alvir JMJ, Lieberman JA. Obstetric complications in schizophrenia, affective disorder and normal controls Schizophrenia Research. 24: 251. DOI: 10.1016/S0920-9964(97)82721-1  0.346
1997 Umbricht D, Javitt D, Bates J, Pollak S, Lieberman J, Kane J. Event-related potentials (ERP) during a visual working memory task in first episode and chronic schizophrenia Schizophrenia Research. 24: 239. DOI: 10.1016/S0920-9964(97)82689-8  0.366
1997 Umbricht D, Javitt D, Bates J, Pollak S, Lieberman J, Kane J. Auditory event-related potentials (ERP) in first episode and chronic schizophrenia Schizophrenia Research. 24: 238-239. DOI: 10.1016/S0920-9964(97)82688-6  0.432
1997 Alvir JMJ, Woerner MG, Gunduz H, Lieberman JA. Obstetric complications predict treatment response in first episode schizophrenia Schizophrenia Research. 24: 204-205. DOI: 10.1016/S0920-9964(97)82587-X  0.356
1997 Robison DG, Lieberman JA, Sheitman B, Alvir JMJ, Kane JM. Pilot study of atypical antipsychotic agents in first episode schizophrenia Schizophrenia Research. 24: 196. DOI: 10.1016/S0920-9964(97)82561-3  0.389
1997 Woerner MG, Gunduz H, Alvir JM, Bilder R, Lieberman JA. Obstetric complications and brain MRI findings in schizophrenia Schizophrenia Research. 24: 160. DOI: 10.1016/S0920-9964(97)82460-7  0.332
1997 Szeszko P, Lencz T, Bilder R, Redmond M, Wu H, Lieberman J. Parcellation of the frontal lobes in first-episode schizophrenia Schizophrenia Research. 24: 158. DOI: 10.1016/S0920-9964(97)82454-1  0.486
1997 Lencz T, Redmond MP, Bookstein FL, Wu H, Bilder RM, Ashtari M, Lieberman JA. MRI landmark shape analysis of neuroanatomy in first-episode schizophrenia Schizophrenia Research. 24: 151. DOI: 10.1016/S0920-9964(97)82431-0  0.372
1997 Crandall DT, Szeszko PR, Bilder RM, Strous R, Lieberman JA. Reduced anterior hippocampal volumes are associated with alternating response patterns in first episode schizophrenia Schizophrenia Research. 24: 141. DOI: 10.1016/S0920-9964(97)82402-4  0.349
1997 Barr WB, Bilder RM, Goldman RS, Lieberman JA. Neuropsychological comparison of executive functions in first-episode schizophrenia and temporal lobe epilepsy Schizophrenia Research. 24: 98. DOI: 10.1016/S0920-9964(97)82265-7  0.324
1997 Vincent JB, Meltzer H, Lieberman J, Breschel T, McGinnis M, Macedo A, Azevedo M, Pato C, Torrey E, Gottesman I, Petronis A, Kennedy J. Large or expanded CAG/CTG trinucleotide repeats as an etiological factor in schizophrenia Schizophrenia Research. 24: 55. DOI: 10.1016/S0920-9964(97)82157-3  0.37
1997 Lieberman JA. Co-morbidity issues in the treatment of schizophrenia Biological Psychiatry. 42: 266S. DOI: 10.1016/S0006-3223(97)88033-X  0.382
1997 Lieberman JA. Atypical antipsychotic drug treatment in the early stages of schizophrenia Biological Psychiatry. 42: 200S. DOI: 10.1016/S0006-3223(97)87739-6  0.346
1997 Lieberman J, Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woemer M, Kane JM, Alvir J. Extrapyramidal signs in dyskinesia in first episode schizophrenia Biological Psychiatry. 42. DOI: 10.1016/S0006-3223(97)87447-1  0.501
1997 Lieberman J, Koreen A, Geisler S, Bilder R, Bogerts B, Alvir J, Cooper T. The psychobiology of first episode schizophrenia Biological Psychiatry. 42: 61S-62S. DOI: 10.1016/S0006-3223(97)87131-4  0.401
1997 Herz MI, Liberman RP, McGlashan TH, Lieberman JA, Wyatt RJ, Marder SR, Wang P, Allgulander C, Baldessarini RJ, Balon R, Bellack AS, Berlin C.M. J, Blackington CH, Buckley P, Carlson DG, et al. Practice guideline for the treatment of patients with schizophrenia American Journal of Psychiatry. 154: 1-63.  0.37
1996 Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis Journal of Clinical Psychiatry. 57: 68-71. PMID 8941173  0.393
1996 Lieberman JA, Alvir JM, Koreen A, Geisler S, Chakos M, Sheitman B, Woerner M. Psychobiologic correlates of treatment response in schizophrenia Neuropsychopharmacology. 14: 13S-21S. PMID 8866739 DOI: 10.1016/0893-133X(95)00200-W  0.361
1996 Sasaki T, Macciardi FM, Badri F, Verga M, Meltzer HY, Lieberman J, Howard A, Bean G, Joffe RT, Hudson CJ, Kennedy JL. No evidence for association of dopamine D2 receptor variant (Ser311/Cys311) with major psychosis. American Journal of Medical Genetics. 67: 415-7. PMID 8837713 DOI: 10.1002/(Sici)1096-8628(19960726)67:4<415::Aid-Ajmg18>3.0.Co;2-M  0.421
1996 Szymanski S, Lieberman J, Pollack S, Kane JM, Safferman A, Munne R, Umbricht D, Woerner M, Masiar S, Kronig M. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics Biological Psychiatry. 39: 249-254. PMID 8645771 DOI: 10.1016/0006-3223(95)00138-7  0.354
1996 Sasaki T, Billett E, Petronis A, Ying D, Parsons T, Macciardi FM, Meltzer HY, Lieberman J, Joffe RT, Ross CA, McInnis MG, Li SH, Kennedy JL. Psychosis and genes with trinucleotide repeat polymorphism. Human Genetics. 97: 244-6. PMID 8566962 DOI: 10.1007/Bf02265274  0.374
1996 Lieberman JA. Pharmacotherapy for Patients with First-Episode, Acute, and Refractory Schizophrenia Psychiatric Annals. 26: 515-518. DOI: 10.3928/0048-5713-19960801-07  0.384
1996 Lieberman J. Evidence for sensitization in the early stage of schizophrenia European Neuropsychopharmacology. 6: 155. DOI: 10.1016/0924-977X(96)88023-0  0.337
1996 Lieberman J. Treatment and consequences of relapse in schizophrenia European Neuropsychopharmacology. 6: 25. DOI: 10.1016/0924-977X(96)87413-X  0.397
1996 Bilder R, Turkel E, Bates J, Lieberman J. Frontolimbic mechanisms for perceptual and response classification in schizophrenia European Psychiatry. 11: 217s-218s. DOI: 10.1016/0924-9338(96)88637-8  0.362
1996 Lencz T, Bilder R, Bogerts B, Ashtari M, Wu H, Alvir J, Schenkler J, Lieberman J. Neuropsychological correlates of prefrontal volume in schizophrenia Biological Psychiatry. 39: 579. DOI: 10.1016/0006-3223(96)84218-1  0.375
1996 Szeszko P, Bilder R, Walder D, Lieberman J. Methylphenidate effects on verbal fluency in schizophrenia Biological Psychiatry. 39: 576. DOI: 10.1016/0006-3223(96)84207-7  0.402
1996 Koreen AR, Sheitman B, Lieberman J. Biological predictors of antipsychotic treatment response Handbook of Experimental Pharmacology. 120: 389-444. DOI: 10.1007/978-3-642-61007-3_14  0.386
1995 Szymanski S, Lieberman J, Pollack S, Safferman A, Munne R, Umbricht D, Kane J, Kronig M, Chakos M, Cooper T. Clozapine effects on neuroendocrine response to apomorphine challenge testing in chronic neuroleptic nonresponsive schizophrenia: Preliminary findings Biological Psychiatry. 37: 52-55. PMID 7893860 DOI: 10.1016/0006-3223(94)00191-5  0.463
1995 Lieberman JA. Signs and Symptoms: What Can They Tell Us About the Clinical Course and Pathophysiologic Processes of Schizophrenia? Archives of General Psychiatry. 52: 361-363. PMID 7726716 DOI: 10.1001/Archpsyc.1995.03950170035005  0.4
1995 Szymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel A, Geisler S, Chakos M, Koreen A, Jody D, Kane J, Woerner M, Cooper T. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients American Journal of Psychiatry. 152: 698-703. PMID 7726309 DOI: 10.1176/Ajp.152.5.698  0.343
1995 Shore D, Matthews S, Cott J, Lieberman JA. Clinical implications of clozapine discontinuation: Report of an NIMH workshop Schizophrenia Bulletin. 21: 333-338. PMID 7543218 DOI: 10.1093/Schbul/21.2.333  0.317
1995 Chakos M, Alvir J, Koreen A, Sheitman B, Geisler S, Lieberman J. Incidence and correlates of acute extrapyramidal symptoms in first episode schizophrenia Schizophrenia Research. 15: 205. DOI: 10.1016/0920-9964(95)95631-I  0.451
1995 Loebel A, Lieberman J, Alvir J, Geisler J, Koreen A, Chakos M. Time to treatment response in successive episodes of early onset schizophrenia Schizophrenia Research. 15: 158. DOI: 10.1016/0920-9964(95)95489-V  0.377
1995 Wilson D, Bilder R, Reiter G, Barr W, Lieberman J. Memory impairment in first episode schizophrenia Schizophrenia Research. 15: 139-140. DOI: 10.1016/0920-9964(95)95434-B  0.305
1995 Bilder R, Reiter G, Bates J, Willson D, Lieberman J. Neuropsychological profiles of first episode schizophrenia Schizophrenia Research. 15: 109. DOI: 10.1016/0920-9964(95)95336-8  0.4
1995 Chakos M, Alvir J, Koreen A, Sheitman B, Geisler S, Lieberman J. Incidence and correlates of acute extrapyramidal symptoms in first episode schizophrenia Biological Psychiatry. 37: 660-661. DOI: 10.1016/0006-3223(95)94652-D  0.451
1994 Szymanski S, Masiar S, Mayerhoff D, Loebel A, Geisler S, Pollack S, Kane J, Lieberman J. Clozapine response in treatment-refractory first-episode schizophrenia Biological Psychiatry. 35: 278-280. PMID 8186332 DOI: 10.1016/0006-3223(94)91259-9  0.393
1994 Bilder RM, Wu H, Bogerts B, Degreef G, Ashtari M, Alvir JM, Snyder PJ, Lieberman JA. Absence of regional hemispheric volume asymmetries in first-episode schizophrenia. The American Journal of Psychiatry. 151: 1437-47. PMID 8092337 DOI: 10.1176/AJP.151.10.1437  0.323
1994 Mayerhoff DI, Loebel AD, Alvir JMJ, Szymanski SR, Geisler SH, Borenstein M, Lieberman JA. The deficit state in first-episode schizophrenia American Journal of Psychiatry. 151: 1417-1422. PMID 8092335  0.387
1994 Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM. Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome American Journal of Psychiatry. 151: 1744-1752. PMID 7977880 DOI: 10.1176/Ajp.151.12.1744  0.361
1994 Safferman AZ, Kane JM, Aronowitz JS, Gordon MF, Pollack S, Lieberman JA. The use of clozapine in neurologic disorders Journal of Clinical Psychiatry. 55: 98-101. PMID 7961585  0.37
1994 Bilder RM, Wu H, Chakos MH, Bogerts B, Pollack S, Aronowitz J, Ashtari M, Degreef G, Kane JM, Lieberman JA. Cerebral morphometry and clozapine treatment in schizophrenia. The Journal of Clinical Psychiatry. 55: 53-6. PMID 7961574  0.389
1994 Koreen AR, Lieberman J, Alvir J, Mayerhoff D, Loebel A, Chakos M, Amin F, Cooper T. Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response. Archives of General Psychiatry. 51: 132-8. PMID 7905259 DOI: 10.1001/Archpsyc.1994.03950020056006  0.426
1994 Lieberman JA, Alvir J, Geisler S, Ramos-Lorenzi J, Woerner M, Novacenko H, Cooper T, Kane JM. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia Neuropsychopharmacology. 11: 107-118. PMID 7840862 DOI: 10.1038/Npp.1994.40  0.393
1994 Waddington JL, Lieberman JA. New insights into classical issues in schizophrenia Journal of Psychopharmacology. 8: 65-66. DOI: 10.1177/026988119400800113  0.374
1994 Umbricht D, Wu H, Barr W, Schaul N, Lieberman J. Ventricular Volumes In Patients With Temporal Lobe Epilepsy And Psychosis Neuropsychopharmacology. 11: 287-287. DOI: 10.1038/Sj.Npp.1380223  0.433
1994 Sheitman B, Lieberman J, Alvir J. Prepubertal Psychosis: A Case Control Study Neuropsychopharmacology. 11: 284-284. DOI: 10.1038/Sj.Npp.1380210  0.329
1994 Chakos M, Alvir J, Bilder R, Woerner M, Kane J, Lieberman J. Predictors of Tardive Dyskinesia in First Episode Schizophrenia Neuropsychopharmacology. 11: 267-267. DOI: 10.1038/Sj.Npp.1380141  0.365
1994 Aronowitz J, Wu H, Pollack S, Bilder R, Kane J, Safferman A, Lieberman J. Clozapine Response In Chronic Schizophrenia And Brain Morphology On MRI: A Preliminary Report Neuropsychopharmacology. 11: 265-265. DOI: 10.1038/Sj.Npp.1380132  0.412
1994 Bell L, Bilder R, Kirk U, Lieberman J. Is frontal lobe dysfunction really generalized deficit in schizophrenia? Biological Psychiatry. 35: 635-636. DOI: 10.1016/0006-3223(94)90734-X  0.385
1993 Lieberman JA, Jody D, Alvir JM, Ashtari M, Levy DL, Bogerts B, Degreef G, Mayerhoff DI, Cooper T. Brain morphology, dopamine, and eye-tracking abnormalities in first-episode schizophrenia. Prevalence and clinical correlates. Archives of General Psychiatry. 50: 357-68. PMID 8489325 DOI: 10.1001/Archpsyc.1993.01820170035005  0.334
1993 Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J. Depression in first-episode schizophrenia. The American Journal of Psychiatry. 150: 1643-8. PMID 8105706 DOI: 10.1176/AJP.150.11.1643  0.357
1993 Lieberman JA, Koreen AR. Neurochemistry and neuroendocrinology of schizophrenia: A selective review Schizophrenia Bulletin. 19: 371-429. PMID 8100644 DOI: 10.1093/Schbul/19.2.371  0.376
1993 Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M. Time course and biologic correlates of treatment response in first-episode schizophrenia. Archives of General Psychiatry. 50: 369-76. PMID 8098203 DOI: 10.1001/Archpsyc.1993.01820170047006  0.377
1993 Lieberman JA, Sobel SN. Predictors of treatment response and course of schizophrenia Current Opinion in Psychiatry. 6: 63-69. DOI: 10.1097/00001504-199302000-00012  0.383
1993 Selzer JA, Lieberman JA. Schizophrenia and Substance Abuse Psychiatric Clinics of North America. 16: 401-412. DOI: 10.1016/S0193-953X(18)30181-3  0.372
1993 Sobel S, Alvir JJ, Mayerhoff D, Koreen A, Chakos M, Lieberman J. Social adjustment and outcome in first episode schizophrenia Schizophrenia Research. 9: 273. DOI: 10.1016/0920-9964(93)90635-V  0.422
1993 Szymanski S, Pollack S, Cooper T, Safferman A, Munne R, Umbricht D, Lieberman J, Kronig M. The dopamine-serotonin relationship in clozapine response Schizophrenia Research. 9: 254. DOI: 10.1016/0920-9964(93)90580-C  0.358
1993 Szymanski S, Mayerhoff D, Koreen A, Lemus C, Alvir J, Loebel A, Munne R, Umbricht D, Sobel S, Lieberman J. Behavioural effects of IV MCPP in schizophrenia Schizophrenia Research. 9: 254. DOI: 10.1016/0920-9964(93)90579-8  0.367
1993 Loebel A, Lieberman J, Alvir J, Geisler S, Szymanski S, Mayerhoff D. Consistency of treatment response across successive psychotic episodes in recent-onset schizophrenia Schizophrenia Research. 9: 243. DOI: 10.1016/0920-9964(93)90544-S  0.4
1993 Koreen A, Lieberman J, Alvir J, Mayerhoff D, Loebel A, Chakos M, Amin F, Cooper T. Plasma homovanillic acid in first-episode schizophrenia: Psychopathology and treatment response Schizophrenia Research. 9: 240. DOI: 10.1016/0920-9964(93)90537-S  0.326
1993 Chakos M, Lieberman J, Bilder R, Lerner G, Bogerts B, Ashtai M. Prospective MRI study of caudate pathomorphology in first episode schizophrenia Schizophrenia Research. 9: 196. DOI: 10.1016/0920-9964(93)90408-B  0.392
1993 Barr W, Ashtari M, Degreef G, Bogerts B, Bilder R, Schaul N, Lieberman J. Brain morphometric comparison of first episode schizophrenia and temporal lobe epilepsy Schizophrenia Research. 9: 192. DOI: 10.1016/0920-9964(93)90394-X  0.31
1993 Lipschutz-Broch L, Bilder R, Turkel E, Reiter G, Lieberman J. A chronometric analysis of executive deficits in acute and stable phases of first episode schizophrenia Schizophrenia Research. 9: 182. DOI: 10.1016/0920-9964(93)90362-M  0.34
1993 Szymanski S, Lieberman J, Pollack S, Kane J, Munne R, Umbricht D, Safferman A, Masiar S, Galkowski B. Gender differences in clozapine treated schizophrenic patients Schizophrenia Research. 9: 111. DOI: 10.1016/0920-9964(93)90149-D  0.33
1992 Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. The American Journal of Psychiatry. 149: 1183-8. PMID 1503130 DOI: 10.1176/AJP.149.9.1183  0.33
1992 Bogerts B, Lieberman JA, Bilder RM, Ashtari M, Degreef G, Lerner G, Johns C, Masiar S. A volumetric MRI study of limbic structures in chronic schizophrenia--relationship to psychopathology. Clinical Neuropharmacology. 15: 112A-113A. PMID 1498773 DOI: 10.1097/00002826-199201001-00061  0.338
1992 Lieberman JA, Alvir JM, Woerner M, Degreef G, Bilder RM, Ashtari M, Bogerts B, Mayerhoff DI, Geisler SH, Loebel A. Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. Schizophrenia Bulletin. 18: 351-71. PMID 1411327 DOI: 10.1093/Schbul/18.3.351  0.389
1992 Degreef G, Bogerts B, Falkai P, Greve B, Lantos G, Ashtari M, Lieberman J. Increased prevalence of the cavum septum pellucidum in magnetic resonance scans and post-mortem brains of schizophrenic patients. Psychiatry Research. 45: 1-13. PMID 1410074 DOI: 10.1016/0925-4927(92)90009-S  0.306
1992 Safferman AZ, Lieberman JA, Pollack S, Kane JM. Clozapine and akathisia Biological Psychiatry. 31: 753-754. PMID 1350924 DOI: 10.1016/0006-3223(92)90291-7  0.316
1992 Lieberman J, Mayerhoff D, Loebel A, Degreef G, Levy D, Alvir J, Ashtari M, Cooper T. BIOLOGIC INDICES OF HETEROGENEITY IN SCHIZOPHRENIA: RELATIONSHIP TO PSYCHOPATHOLOGY AND TREATMENT OUTCOME Clinical Neuropharmacology. 15: 168B. DOI: 10.1097/00002826-199202001-00324  0.355
1992 Lieberman JA, Matthews SM, Kirch DG. First-episode psychosis: Part II. Editors' introduction Schizophrenia Bulletin. 18: 349-350. DOI: 10.1093/schbul/18.3.349  0.364
1992 Mayerhoff D, Loebel A, Geisler S, Szymanski S, Borenstein M, Lieberman J. The deficit state in a prospective study of first-episode schizophrenia Schizophrenia Research. 6: 168-169. DOI: 10.1016/0920-9964(92)90270-F  0.374
1992 Bogerts B, Lieberman J, Ashtari M, DeGreef G, Lerner G. Temporal limbic structure volumes and psychopathology in chronic schizophrenia Schizophrenia Research. 6: 143. DOI: 10.1016/0920-9964(92)90208-M  0.344
1992 Lieberman J, Mayerhoff D, Loebel A, Geisler S, Alvir J. Evidence for sensitization in the early stage of schizophrenia Schizophrenia Research. 6: 109. DOI: 10.1016/0920-9964(92)90133-P  0.337
1991 Robinson D, Mayerhoff D, Alvir J, Cooper T, Lieberman J. Mood responses of remitted schizophrenics to methylphenidate infusion. Psychopharmacology. 105: 247-252. PMID 1796130 DOI: 10.1007/Bf02244317  0.424
1991 Degreef G, Ashtari M, Wu HW, Borenstein M, Geisler S, Lieberman J. Follow up MRI study in first episode schizophrenia. Schizophrenia Research. 5: 204-6. PMID 1760397 DOI: 10.1016/0006-3223(91)91252-M  0.487
1991 Bilder RM, Lipschutz-Broch L, Reiter G, Geisler S, Mayerhoff D, Lieberman JA. Neuropsychological deficits in the early course of first episode schizophrenia. Schizophrenia Research. 5: 198-9. PMID 1760394 DOI: 10.1016/0920-9964(91)90071-X  0.39
1991 Szymanski S, Kane JM, Lieberman JA. A selective review of biological markers in schizophrenia Schizophrenia Bulletin. 17: 99-111. PMID 1675484 DOI: 10.1093/Schbul/17.1.99  0.385
1991 Bilder R, Kipschultz-Broch L, Reiter G, Mayerhoff D, Loebel A, Degreef G, Ashtari M, Lieberman J. Neuropsychological studies of first episode schizophrenia Schizophrenia Research. 4: 381-382. DOI: 10.1016/0920-9964(91)90315-I  0.407
1991 Loebel A, Lieberman J, Mayerhoff D, Jody D, Szymanski S, Geisler S, Borenstein M, Ma Alvir J. Correlates of course and outcome in first-episode schizophrenia Schizophrenia Research. 4: 290. DOI: 10.1016/0920-9964(91)90166-O  0.352
1991 Lieberman J, Mayerhoff D, Loebel A, Degreef G, Levy D, Alvir J. Biologic indices of heterogeneity in schizophrenia: Relationship to psychopathology and treatment outcome Schizophrenia Research. 4: 289-290. DOI: 10.1016/0920-9964(91)90165-N  0.355
1991 DeLisi LE, Lieberman J. Longitudinal perspectives on the pathophysiology of schizophrenia : examining the neurodevelopmental versus neurodegenerative hypotheses : selected papers, December 8, 1990, San Juan Schizophrenia Research. 5: 183-210. DOI: 10.1016/0920-9964(91)90060-5  0.483
1990 Bogerts B, Ashtari M, Degreef G, Alvir JM, Bilder RM, Lieberman JA. Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia. Psychiatry Research. 35: 1-13. PMID 2367608 DOI: 10.1016/0925-4927(90)90004-P  0.329
1990 Lieberman JA, Kinon BJ, Loebel AD. Dopaminergic mechanisms in idiopathic and drug-induced psychoses Schizophrenia Bulletin. 16: 97-110. PMID 2185538 DOI: 10.1093/Schbul/16.1.97  0.324
1989 Lieberman J, Lesser M, Johns C, Pollack S, Saltz B, Kane J. Pharmacologic studies of tardive dyskinesia. Journal of Clinical Psychopharmacology. 8: 57S-63S. PMID 3220968 DOI: 10.1097/00004714-198808001-00010  0.317
1989 Lieberman J, Johns C, Cooper T, Pollack S, Kane J. Clozapine pharmacology and tardive dyskinesia Psychopharmacology. 99. PMID 2479047 DOI: 10.1007/Bf00442560  0.45
1989 Lieberman J, Johns C, Cooper T, Kane J. Biochemical effects of clozapine in schizophrenia Schizophrenia Research. 2: 164. DOI: 10.1016/0920-9964(89)90200-4  0.498
1989 Lieberman J, Jody D, Geisler S, Vital-Herne J, Alvir J, Walsleben J. Brain morphology, dopamine and outcome in first episode schizophrenia Schizophrenia Research. 2: 163. DOI: 10.1016/0920-9964(89)90199-0  0.436
1989 Szymanski S, Lieberman J, Zito J, Ashtari M, DeGreef G. A study using gadopenetetate dimeglumine enhanced MRI scans in schizophrenia Schizophrenia Research. 2: 131. DOI: 10.1016/0920-9964(89)90167-9  0.37
1989 Lieberman JA. Ethics of Drug Discontinuation Studies in Schizophrenia-Reply Archives of General Psychiatry. 46: 387. DOI: 10.1001/Archpsyc.1989.0181004009321  0.39
1988 LIEBERMAN J, POLLACK S, LESSER M, KANE J. Pharmacologic Characterization of Tardive Dyskinesia Journal of Clinical Psychopharmacology. 8: 254???260. DOI: 10.1097/00004714-198808000-00004  0.317
1987 Lieberman JA, Kane JM, Sarantakos S, Gadaleta D, Woerner M, Alvir J, Ramos-Lorenzi J. Prediction of relapse in schizophrenia. Archives of General Psychiatry. 44: 597-603. PMID 2886110 DOI: 10.1001/Archpsyc.1987.01800190013002  0.357
1984 Lieberman J. Evidence for a biological hypothesis of obsessive-compulsive disorder Neuropsychobiology. 11: 14-21. PMID 6204247 DOI: 10.1159/000118043  0.301
1984 Lieberman JA, Kane JM, Gadaleta D, Brenner R, Lesser MS, Kinon B. Methylphenidate challenge as a predictor of relapse in schizophrenia. The American Journal of Psychiatry. 141: 633-8. PMID 6143506 DOI: 10.1176/AJP.141.5.633  0.343
Show low-probability matches.